Quick Answer
KalVista Pharmaceuticals, Inc. reported Research And Development Expense of $71.71 million for the year ending 2025.
- KalVista Pharmaceuticals, Inc. showed a decrease of -16.8% in Research And Development Expense from 2024 to 2025.
- This data is from KalVista Pharmaceuticals, Inc.'s annual report (Form 10-K), filed with the SEC on July 10, 2025.
- XBRL data for this metric is available from 2013 to 2025 (14 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Over the full 14 years of available data (2013 to 2025), KalVista Pharmaceuticals, Inc.'s Research And Development Expense has grown by 1,595.6%.
- Historical annual values: Fiscal year 2025: $71.71 million | Fiscal year 2024: $86.17 million | Fiscal year 2023: $80.28 million | Fiscal year 2022: $70.17 million | Fiscal year 2021: $41.29 million | Fiscal year 2020: $40.19 million | Fiscal year 2019: $35.02 million | Fiscal year 2018: $18.24 million | Fiscal year 2017: $12.67 million | Fiscal year 2016: $14.66 million | Fiscal year 2015: $16.20 million | Fiscal year 2015: $8.29 million | Fiscal year 2014: $8.29 million | Fiscal year 2013: $4.23 million.
- Data sourced from SEC EDGAR public filings as of June 20, 2026.
Last verified: